Insulin inhalation (Dong Sung/Biocon)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameInsulin inhalation (Dong Sung/Biocon)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiocon Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCpex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A